We are live on
!
Find out more
Bellevue Group Portfolio holdings
AUM
$4.75B
Turnover
23.84%
1-Year Est. Return
68.58%
This Fund
S&P 500
This Quarter
Est. Return
+16.34%
1 Year Est. Return
+68.58%
3 Year Est. Return
+159.39%
5 Year Est. Return
+187.79%
10 Year Est. Return
+1,025.09%
AUM
$4.75B
AUM Growth
+$551M
(+13%)
Cap. Flow
+$76.2M
Cap. Flow
% of AUM
1.6%
Top 10 Holdings %
Top 10 Hldgs %
42.9%
Holding
172
New
17
Increased
41
Reduced
66
Closed
24
Avg Time Held
4
years
Top 10 Avg Time Held
1.7
years
Top 20 Avg Time Held
1.7
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$190M |
| 2 |
Insmed
INSM
|
+$168M |
| 3 |
Gilead Sciences
GILD
|
+$130M |
| 4 |
United Therapeutics
UTHR
|
+$105M |
| 5 |
BridgeBio Pharma
BBIO
|
+$81.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Krystal Biotech
KRYS
|
+$121M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
+$82.6M |
| 3 |
Revolution Medicines
RVMD
|
+$72.5M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
+$70.4M |
| 5 |
Ionis Pharmaceuticals
IONS
|
+$63.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.91% |
| 2 | Miscellaneous | 0.05% |
| 3 | Technology | 0.03% |
| 4 | Communication Services | 0.01% |
| 5 | Consumer Discretionary | 0.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
126
Cardinal Health
CAH
$58.8B
| $202K | ﹤0.01% |
852
-11
| -1% | -$2.29K |
2023 Q4
10 quarters
|
|
127
Cogent Biosciences
COGT
$5.12B
| $188K | ﹤0.01% |
+4,870
| New | +$170K |
2026 Q2
0 quarters
|
|
128
Tempus AI
TEM
$12B
| $186K | ﹤0.01% |
3,213
-1,737
| -35% | -$87.1K |
2024 Q2
8 quarters
|
|
129
Cencora
COR
$65.2B
| $163K | ﹤0.01% |
576
-1,140
| -66% | -$329K |
2022 Q1
17 quarters
|
|
130
PTC Therapeutics
PTCT
$4.96B
| $133K | ﹤0.01% |
1,626
-309
| -16% | -$22.3K |
2024 Q4
6 quarters
|
|
131
Caris Life Sciences
CAI
$8.75B
| $114K | ﹤0.01% |
6,418
| – | – |
2025 Q2
4 quarters
|
|
132
Rhythm Pharmaceuticals
RYTM
$5.96B
| $113K | ﹤0.01% |
1,016
| – | – |
2023 Q3
11 quarters
|
|
133
Arrowhead Research
ARWR
$8.02B
| $97.1K | ﹤0.01% |
1,191
-354
| -23% | -$26.1K |
2025 Q4
2 quarters
|
|
134
NVIDIA
NVDA
$5.25T
| $81.6K | ﹤0.01% |
408
| – | – |
2023 Q4
10 quarters
|
|
135
Labcorp
LH
$25.9B
| $78.4K | ﹤0.01% |
280
| – | – |
2016 Q1
41 quarters
|
|
136
Biogen
BIIB
$34.8B
| $73K | ﹤0.01% |
338
-3,315
| -91% | -$634K |
2020 Q3
23 quarters
|
|
137
Bristol-Myers Squibb
BMY
$124B
| $70.1K | ﹤0.01% |
1,216
-15,822
| -93% | -$909K |
2024 Q3
7 quarters
|
|
138
Waters Corp
WAT
$42.8B
| $67.1K | ﹤0.01% |
+179
| New | +$61.1K |
2026 Q2
0 quarters
|
|
139
Microsoft
MSFT
$3.93T
| $64.2K | ﹤0.01% |
172
| – | – |
2023 Q4
10 quarters
|
|
140
IQVIA
IQV
$44.1B
| $56.6K | ﹤0.01% |
293
-447
| -60% | -$77.9K |
2020 Q1
25 quarters
|
|
141
Incyte
INCY
$22.8B
| $55.1K | ﹤0.01% |
486
| – | – |
2016 Q1
41 quarters
|
|
142
Mettler-Toledo International
MTD
$32.8B
| $46K | ﹤0.01% |
36
| – | – |
2023 Q4
10 quarters
|
|
143
Agilent Technologies
A
$48.9B
| $43.8K | ﹤0.01% |
330
-334
| -50% | -$40.7K |
2023 Q4
10 quarters
|
|
144
Qualcomm
QCOM
$189B
| $36.4K | ﹤0.01% |
197
| – | – |
2023 Q4
10 quarters
|
|
145
Zoetis
ZTS
$32.8B
| $28K | ﹤0.01% |
390
-143
| -27% | -$13.5K |
2023 Q1
13 quarters
|
|
146
Oracle
ORCL
$393B
| $28K | ﹤0.01% |
191
| – | – |
2023 Q4
10 quarters
|
|
147
Quest Diagnostics
DGX
$25.9B
| $27.8K | ﹤0.01% |
131
| – | – |
2025 Q2
4 quarters
|
|
148
Recursion Pharmaceuticals
RXRX
$1.93B
| $17K | ﹤0.01% |
4,627
| – | – |
2023 Q3
11 quarters
|
|
149
Accenture
ACN
$139B
| – | – |
-1,500
| Closed | -$297K | – |
|
150
Adobe
ADBE
$95.4B
| – | – |
-1,200
| Closed | -$292K | – |
|
Similar funds
PTC
Bellevue Group's Q2 2026 Portfolio in Review
As of Q2 2026, Bellevue Group held 172 positions worth $4.75B, up 13% from $4.2B the previous quarter. Its ten largest holdings account for 43% of the portfolio.
Bellevue Group's Q2 2026 filing shows 17 new, 41 increased, 66 reduced and 24 closed positions. Its largest new stake was Avalyn Pharma: 1,350,000 shares worth $44.4M. The largest sale was Krystal Biotech, an estimated $121M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous and Technology.
- Bellevue Group's largest Q2 2026 buy was Avalyn Pharma: 1,350,000 shares worth $44.4M.
- Bellevue Group added most to Amgen in Q2 2026, an estimated $190M increase.
- Bellevue Group's biggest Q2 2026 reduction was Krystal Biotech, cutting an estimated $121M.
- Bellevue Group fully exited Edgewise Therapeutics in Q2 2026, selling an estimated $48.1M.
- Bellevue Group's ten largest holdings make up 43% of its $4.75B portfolio in Q2 2026.
- Bellevue Group opened 17 new positions and closed 24 in Q2 2026.
- Bellevue Group's portfolio value rose 13% quarter-over-quarter to $4.75B.
Based on Bellevue Group's 13F filing for Q2 2026, filed 14 Aug 2026.